Status:
COMPLETED
Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment
Lead Sponsor:
Medical University of Vienna
Conditions:
HPV
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The occurance and clinical course of human papillomavirus (HPV)-induced lesions is largely determined by the nature of the cellular immune defense generated. Even tough both genital warts and vulvar i...
Eligibility Criteria
Inclusion
- Female patients with histologically proven Vulvar Intraepithelial Neoplasia 2/3 and/or anogenital Condyloma acuminata
- Age 18-50
- Informed consent
Exclusion
- Malignancy
- Pregnancy
- Therapeutic Immunosupression
- Severe systemic dermatologic disease
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00941811
Start Date
December 1 2008
End Date
May 1 2010
Last Update
June 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stephan Polterauer
Vienna, Austria, A-1090